EP0660703A1 - Topisch anzuwendende arzneimittel enthaltend kohlensäureanhydraseinhibitoren - Google Patents

Topisch anzuwendende arzneimittel enthaltend kohlensäureanhydraseinhibitoren

Info

Publication number
EP0660703A1
EP0660703A1 EP93906043A EP93906043A EP0660703A1 EP 0660703 A1 EP0660703 A1 EP 0660703A1 EP 93906043 A EP93906043 A EP 93906043A EP 93906043 A EP93906043 A EP 93906043A EP 0660703 A1 EP0660703 A1 EP 0660703A1
Authority
EP
European Patent Office
Prior art keywords
carbonic anhydrase
anhydrase inhibitor
composition
sulfonamide
thieno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93906043A
Other languages
English (en)
French (fr)
Inventor
Thomas Robert Dean
Jesse Albert May
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of EP0660703A1 publication Critical patent/EP0660703A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the polycyclic heteroaromatic group can be, for example, two fused five membered aromatic rings with one or more heteroatoms such as 0, S, N; examples include: thienothiophenes, thienofurans, thienopyrroles, furanothiophenes, imidazolthiazoles and, thienothiazoles.
  • the polycylic heteroaromatic group can also be a five- embered heteroaromatic ring fused to a six-membered carbocyclic or heterocyclic ring which may or may not be aromatic. Examples include: benzothiophene, thienothiazines, thienothiopyrans or furanothiopyrans.
  • composition includes the compound R-(+)-4- ethylamino-3,4-dihydro-2-(3-methoxy)propyl-2H-thieno[3,2-e]- 1,2-thiazine-6-sulfonamide 1,1-dioxide.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP93906043A 1992-09-17 1993-02-18 Topisch anzuwendende arzneimittel enthaltend kohlensäureanhydraseinhibitoren Withdrawn EP0660703A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94650892A 1992-09-17 1992-09-17
US946508 1992-09-17
PCT/US1993/001434 WO1994006411A1 (en) 1992-09-17 1993-02-18 Topical carbonic anhydrase inhibitor composition

Publications (1)

Publication Number Publication Date
EP0660703A1 true EP0660703A1 (de) 1995-07-05

Family

ID=25484578

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93906043A Withdrawn EP0660703A1 (de) 1992-09-17 1993-02-18 Topisch anzuwendende arzneimittel enthaltend kohlensäureanhydraseinhibitoren

Country Status (5)

Country Link
EP (1) EP0660703A1 (de)
JP (1) JPH08501303A (de)
AU (1) AU3722793A (de)
CA (1) CA2141879A1 (de)
WO (1) WO1994006411A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754712B1 (fr) 1996-10-17 1999-09-03 Merck Sharp Dohme Chibret Lab Compositions ophtalmiques
JP6487452B2 (ja) * 2014-01-24 2019-03-20 センティス ファーマ プライベート リミテッド ブリンゾラミドを含む医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153192A (en) * 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
IE911192A1 (en) * 1990-04-12 1991-10-23 Merck & Co Inc Substituted aromatic sulfonamides as antiglaucoma agents
US5157129A (en) * 1990-04-18 1992-10-20 Merck & Co., Inc. Enantiospecific synthesis of s-(+)-5,6-dihydro-4-(r-amino)-4h-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
US5091409A (en) * 1990-05-17 1992-02-25 Merck & Co., Inc. 4-alkylamino-6-(C3-5 -hydrocarbyl)thieno[2,3-B]thiopyran-2-sulfonamide-7,7-dioxides
US5093332A (en) * 1990-10-01 1992-03-03 Merck & Co., Inc. Substituted thieno(2,3-b)(1,4)thiazine-6-sulfonamides as antiglaucoma agents
JP2594486B2 (ja) * 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5175284A (en) * 1991-10-15 1992-12-29 Merck & Co., Inc. Tricyclic thienothiopyrans as pharmaceutical intermediates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9406411A1 *

Also Published As

Publication number Publication date
JPH08501303A (ja) 1996-02-13
AU3722793A (en) 1994-04-12
WO1994006411A1 (en) 1994-03-31
CA2141879A1 (en) 1994-03-31

Similar Documents

Publication Publication Date Title
US6806268B2 (en) Method for treating glaucoma V
US11957691B2 (en) Drug for preventing and/or treating polycystic kidney disease
JP4934653B2 (ja) Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
US5180721A (en) Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
EP0399791A1 (de) Zusammensetzung selektiver alpha-adrenergischer Agonisten und Antagonisten zur Erniedrigung des intraokularen Druckes
US5583150A (en) 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
CA2368242A1 (en) Combination therapy for treating glaucoma
KR100499903B1 (ko) 안압 제어 및 녹내장 치료용 5ｈｔ2 효능제
CA2291777A1 (en) Ophthalmic compositions for treating ocular hypertension
IL95412A (en) Pharmaceutical preparation for the treatment of eye diseases containing 5-methyl-oxazole-4-carboxylic acid anilides and cyanoacetic acid 2-hydroxyethylidine anilides
US5151440A (en) Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenyl-amino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
CA2294343A1 (en) Method for optimizing retinal and optic nerve health
WO1994006411A1 (en) Topical carbonic anhydrase inhibitor composition
EP0625903B1 (de) Topische Antiglaukoma Zusammensetzungen, enthaltend Karbonhydrasehemmer und Beta-Blocker
CZ285129B6 (cs) Oftalmické přípravky, obsahující kombinace inhibitoru karboanhydrasy a beta-adrenergního antagonisty
US6248735B1 (en) Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
US5252595A (en) Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
EP0382537B1 (de) 5-Carbamoylthieno(2,3-B)thiophen-2-sulfonamide als topisch aktive Kohlensäureanhydraseinhibitoren
EP0608604A1 (de) Ajmalin zur Reduktion erhöhten Innenaugendrucks
EP0258476B1 (de) Aldose-Reductase-Hemmer, nützlich bei der Behandlung von Glaukom
EP0277814B1 (de) Verwendung von Trifluormethansulfonamid gegen Glaukom
JPH03271291A (ja) 点眼剤
AU2002312128A1 (en) Method for treating glaucoma V
CA2005753A1 (en) Angiotensin converting enzyme inhibitors in the treatment of glaucoma

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950408

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19951220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19960702